An in-silico study to identify potent phytochemicals for reducing neurotoxicity triggered by calpain and CDK5/p25

Mahir Azmal1, Jibon Kumar Paul1, Omar Faruk Talukder1

  • 1Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh.

Insights

Strobopinin shows potential as a dual inhibitor for neurodegenerative diseases by targeting both CDK5/p25 and calpain. This phytochemical offers a promising avenue for neuroprotective therapies against these debilitating conditions.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Computational Chemistry

Background:

  • Cyclin-dependent kinase 5 (CDK5) dysregulation, particularly via p25 association, is implicated in neurodegenerative diseases.
  • Calpain activity also contributes to neurotoxicity, making it a relevant target for therapeutic intervention.

Purpose of the Study:

  • To identify phytochemical inhibitors targeting both CDK5/p25 and calpain using in silico methods.
  • To evaluate the binding affinity and stability of identified compounds through molecular docking and dynamics simulations.

Main Methods:

  • Screening of 750 phytochemicals from Dr. Duke's Database, followed by ADMET profiling.
  • Molecular docking and 100 ns molecular dynamics simulations of selected compounds against CDK5/p25 and calpain.
  • Density functional theory (DFT) calculations to assess electronic properties and reactivity.

Main Results:

  • Strobopinin demonstrated superior binding affinity for both CDK5/p25 (-8.84 kcal/mol) and calpain (-6.74 kcal/mol) compared to controls.
  • Molecular dynamics simulations indicated stable interaction of strobopinin with CDK5/p25, while the calpain complex showed higher fluctuations.
  • DFT analysis suggested increased chemical reactivity of the strobopinin-calpain complex.

Conclusions:

  • Strobopinin acts as a potential dual inhibitor, mitigating CDK5/p25 hyperactivation and calpain-mediated neurotoxicity.
  • This dual inhibition strategy presents strobopinin as a promising candidate for neuroprotective therapies.
  • Further experimental validation is crucial to confirm efficacy and clinical applicability for neurodegenerative diseases.